EGFR signals to mTOR through PKC and independently of Akt in glioma

Science Signaling

Volumn 2, Issue 55, 2009, Pages

  Fan, Qi Wen ^a,b,c   Cheng, Christine ^a,b,c   Knight, Zachary A ^a,b   Haas Kogan, Daphne ^b,c   Stokoe, David ^b,c   James, C David ^b,c   McCormick, Frank ^c   Shokat, Kevan M ^a,b   Weiss, William A ^a,b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN KINASE C; PROTEIN S6; ENZYME INHIBITOR; PROTEIN KINASE;

ARTICLE; CELL PROLIFERATION; CELL VIABILITY; GENETIC CODE; GLIOMA; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; WILD TYPE; BIOLOGICAL MODEL; BRAIN TUMOR; GENE EXPRESSION REGULATION; METABOLISM; TUMOR CELL LINE;

MAMMALIA; PHOS;

1-PHOSPHATIDYLINOSITOL 3-KINASE; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOMA; HUMANS; MODELS, BIOLOGICAL; PROTEIN KINASE C; PROTEIN KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 62349110027     PISSN: 19450877     EISSN: 19379145     Source Type: Journal    
DOI: 10.1126/scisignal.2000014     Document Type: Article

References (31)

1. A. Gschwind, O. M. Fischer, A. Ullrich, The discovery of receptor tyrosine kinases: Targets for cancer therapy. Nat. Rev. Cancer 4, 361-370 (2004). (Pubitemid 38579482)
2. C. K. Cheng, Q. W. Fan, W. A. Weiss, PI3K signaling in glioma - Animal models and therapeutic challenges. Brain Pathol. 19, 112-120 (2009).
3. I. K. Mellinghoff, M. Y. Wang, I. Vivanco, D. A. Haas-Kogan, S. Zhu, E. Q. Dia, K. V. Lu, K. Yoshimoto, J. H. Huang, D. J. Chute, B. L. Riggs, S. Horvath, L. M. Liau, W. K. Cavenee, P. N. Rao, R. Beroukhim, T. C. Peck, J. C. Lee, W. R. Sellers, D. Stokoe, M. Prados, T. F. Cloughesy, C. L. Sawyers, P. S. Mischel, Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N. Engl. J. Med. 353, 2012-2024 (2005).
4. Q. W. Fan, K. M. Specht, C. Zhang, D. D. Goldenberg, K. M. Shokat, W. A. Weiss, Combinatorial efficacy achieved through two-point blockade within a signaling pathway - A chemical genetic approach. Cancer Res. 63, 8930-8938 (2003).
5. D. A. Haas-Kogan, M. D. Prados, T. Tihan, D. A. Eberhard, N. Jelluma, N. D. Arvold, R. Baumber, K. R. Lamborn, A. Kapadia, M. Malec, M. S. Berger, D. Stokoe, Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J. Natl. Cancer Inst. 97, 880-887 (2005).
6. Q. W. Fan, Z. A. Knight, D. D. Goldenberg, W. Yu, K. E. Mostov, D. Stokoe, K. M. Shokat, W. A. Weiss, A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell 9, 341-349 (2006).
7. M. Y. Wang, K. V. Lu, S. Zhu, E. Q. Dia, I. Vivanco, G. M. Shackleford, W. K. Cavenee, I. K. Mellinghoff, T. F. Cloughesy, C. L. Sawyers, P. S. Mischel, Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells. Cancer Res. 66, 7864-7869 (2006).
8. Q. W. Fan, C. K. Cheng, T. P. Nicolaides, C. S. Hackett, Z. A. Knight, K. M. Shokat, W. A. Weiss, A dual phosphoinositide-3-kinase α/mTOR inhibitor cooperates with blockade of epidermal growth factor receptor in PTEN-mutant glioma. Cancer Res. 67, 7960-7965 (2007).
9. C. W. Lindsley, Z. Zhao, W. H. Leister, R. G. Robinson, S. F. Barnett, D. Defeo-Jones, R. E. Jones, G. D. Hartman, J. R. Huff, H. E. Huber, M. E. Duggan, Allosteric Akt (PKB) inhibitors: Discovery and SAR of isozyme selective inhibitors. Bioorg. Med. Chem. Lett. 15, 761-764 (2005).
10. B. D. Manning, L. C. Cantley, AKT/PKB signaling: Navigating downstream. Cell 129, 1261-1274 (2007).
11. A. C. Schmid, R. D. Byrne, R. Vilar, R. Woscholski, Bisperoxovanadium compounds are potent PTEN inhibitors. FEBS Lett. 566, 35-38 (2004).
12. E. M. Griner, M. G. Kazanietz, Protein kinase C and other diacylglycerol effectors in cancer. Nat. Rev. Cancer 7, 281-294 (2007).
13. J. N. Sarkaria, B. L. Carlson, M. A. Schroeder, P. Grogan, P. D. Brown, C. Giannini, K. V. Ballman, G. J. Kitange, A. Guha, A. Pandita, C. D. James, Use of an orthotopic xenograft model for assessing the effect of epidermal growth factor receptor amplification on glioblastoma radiation response. Clin. Cancer Res. 12, 2264-2271 (2006).
14. J. W. Soh, E. H. Lee, R. Prywes, I. B. Weinstein, Novel roles of specific isoforms of protein kinase C in activation of the c-fos serum response element. Mol. Cell. Biol. 19, 1313-1324 (1999).
15. D. Toullec, P. Pianetti, H. Coste, P. Bellevergue, T. Grand-Perret, M. Ajakane, V. Baudet, P. Boissin, E. Boursier, F. Loriolle, L. Duhamel, D. Charon, J. Kirilovsky, The bisindolylmaleimide GF 109203X is a potent and selective inhibitor of protein kinase C. J. Biol. Chem. 266, 15771-15781 (1991).
16. Z. Kiss, H. Phillips, W. H. Anderson, The bisindolylmaleimide GF 109203X, a selective inhibitor of protein kinase C, does not inhibit the potentiating effect of phorbol ester on ethanol-induced phospholipase C-mediated hydrolysis of phosphatidylethanolamine. Biochim. Biophys. Acta 1265, 93-95 (1995).
17. J. M. Stommel, A. C. Kimmelman, H. Ying, R. Nabioullin, A. H. Ponugoti, R. Wiedemeyer, A. H. Stegh, J. E. Bradner, K. L. Ligon, C. Brennan, L. Chin, R. A. DePinho, Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 318, 287-290 (2007).
18. J. A. Le Good, W. H. Ziegler, D. B. Parekh, D. R. Alessi, P. Cohen, P. J. Parker, Protein kinase C isotypes controlled by phosphoinositide 3-kinase through the protein kinase PDK1. Science 281, 2042-2045 (1998).
19. E. M. Dutil, A. Toker, A. C. Newton, Regulation of conventional protein kinase C isozymes by phosphoinositide-dependent kinase 1 (PDK-1). Curr. Biol. 8, 1366-1375 (1998).
20. T. Ikenoue, K. Inoki, Q. Yang, X. Zhou, K. L. Guan, Essential function of TORC2 in PKC and Akt turn motif phosphorylation, maturation and signalling. EMBO J. 27, 1919-1931 (2008).
21. V. Facchinetti, W. Ouyang, H. Wei, N. Soto, A. Lazorchak, C. Gould, C. Lowry, A. C. Newton, Y. Mao, R. Q. Miao, W. C. Sessa, J. Qin, P. Zhang, B. Su, E. Jacinto, The mammalian target of rapamycin complex 2 controls folding and stability of Akt and protein kinase C. EMBO J. 27, 1932-1943 (2008).
22. E. Galanis, J. C. Buckner, M. J. Maurer, J. I. Kreisberg, K. Ballman, J. Boni, J. M. Peralba, R. B. Jenkins, S. R. Dakhil, R. F. Morton, K. A. Jaeckle, B. W. Scheithauer, J. Dancey, M. Hidalgo, D. J. Walsh, Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: A North Central Cancer Treatment Group Study. J. Clin. Oncol. 23, 5294-5304 (2005). (Pubitemid 46206983)
23. T. F. Cloughesy, K. Yoshimoto, P. Nghiemphu, K. Brown, J. Dang, S. Zhu, T. Hsueh, Y. Chen, W. Wang, D. Youngkin, L. Liau, N. Martin, D. Becker, M. Bergsneider, A. Lai, R. Green, T. Oglesby, M. Koleto, J. Trent, S. Horvath, P. S. Mischel, I. K. Mellinghoff, C. L. Sawyers, Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med. 5, e8 (2008).
24. Y. Shi, H. Yan, P. Frost, J. Gera, A. Lichtenstein, Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade. Mol. Cancer Ther. 4, 1533-1540 (2005).
25. S. Y. Sun, L. M. Rosenberg, X. Wang, Z. Zhou, P. Yue, H. Fu, F. R. Khuri, Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res. 65, 7052-7058 (2005).
26. K. E. O'Reilly, F. Rojo, Q. B. She, D. Solit, G. B. Mills, D. Smith, H. Lane, F. Hofmann, D. J. Hicklin, D. L. Ludwig, J. Baselga, N. Rosen, mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 66, 1500-1508 (2006).
27. S. M. Maira, F. Stauffer, J. Brueggen, P. Furet, C. Schnell, C. Fritsch, S. Brachmann, P. Chene, A. De Pover, K. Schoemaker, D. Fabbro, D. Gabriel, M. Simonen, L. Murphy, P. Finan, W. Sellers, C. Garcia-Echeverria, Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol. Cancer Ther. 7, 1851-1863 (2008).
28. 2M. Oncogene 24, 829-837 (2005).
29. L. Chesler, C. Schlieve, D. D. Goldenberg, A. Kenney, G. Kim, A. McMillan, K. K. Matthay, D. Rowitch, W. A. Weiss, Inhibition of phosphatidylinositol 3-kinase destabilizes Mycn protein and blocks malignant progression in neuroblastoma. Cancer Res. 66, 8139-8146 (2006).
30. R. Nakagawa, J. W. Soh, A. M. Michie, Subversion of protein kinase Cα signaling in hematopoietic progenitor cells results in the generation of a B-cell chronic lymphocytic leukemia-like population in vivo. Cancer Res. 66, 527-534 (2006).
31. This work was supported by grants from the Burroughs Wellcome Fund, the Brain Tumor Society, the Howard Hughes Medical Institute, the Samuel Waxman Cancer Research Foundation, and the National Cancer Institute Specialized Program of Research Excellence. We thank R. Messing for advice; M. Grimmer, C. Hackett, T. Nicolaides, and D. Ruggero for critical review; and J.-W. Soh for providing genetic PKC reagents.